Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22064351 | 1.00 | ALDH1A1 (0.47) | ALDH1A1POLBHTTHSD17B10SMN1; SMN2 | |
| SCHEMBL18924126 | 0.89 | ALDH1A1 (0.48) | ALDH1A1POLBHTTHSD17B10SMN1; SMN2 | |
| SCHEMBL17570905 | 0.89 | ALDH1A1 (0.48) | ALDH1A1POLBHTTHSD17B10SMN1; SMN2 | |
| SCHEMBL22064568 | 0.74 | ALDH1A1 (0.66) | ALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL18924125 | 0.74 | PSMB5 (0.41) | ALDH1A1POLBHTTSMN1; SMN2MTNR1A | |
| SCHEMBL17570904 | 0.74 | PSMB5 (0.41) | ALDH1A1POLBHTTSMN1; SMN2MTNR1A | |
| SCHEMBL18924053 | 0.70 | PSMB5 (0.38) | ALDH1A1HTTHSD17B10SMN1; SMN2 | |
| SCHEMBL2576767 | 0.68 | KMT2A (0.44) | ALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL2576766 | 0.68 | KMT2A (0.44) | ALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL18924055 | 0.67 | PSMB5 (0.44) | ALDH1A1POLBHTTHSD17B10MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9669102-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160082114-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016036801-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | ALDH1A1 695/4885POLB 2910/4885HTT 3818/4885 |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | ALDH1A1 695/4885POLB 2910/4885HTT 3818/4885 |
| US-20160082114-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | ALDH1A1 695/4885POLB 2910/4885HTT 3818/4885 |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | ALDH1A1 695/4885POLB 2910/4885HTT 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.